ArticleCase reports in dermatology
Successful Treatment of Necrobiosis Lipoidica with Abrocitinib: A Case Report.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines. Case Presentation: We present a case of a patient who experienced ulcerative NL of the left leg for 5 years, during which traditional treatments proved ineffective. The patient was administered oral abrocitinib at a dosage of 100 mg per day. After 2 weeks of treatment, the patient's skin lesions ceased exuding and began to show improvement. By the 10-week mark, the patient's symptoms had significantly improved, with the ulcer healing and no new lesions appearing. No adverse events were reported during the 4-month follow-up period. Conclusion: Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL. Further studies are warranted to confirm these findings and evaluate long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.